Roth Capital Forecasts Lower Earnings for Zevra Therapeutics

Zevra Therapeutics, Inc. (NASDAQ:ZVRA - Free Report) - Equities research analysts at Roth Capital decreased their FY2024 earnings per share estimates for shares of Zevra Therapeutics in a research report issued to clients and investors on Tuesday, November 12th. Roth Capital analyst J. Aschoff now forecasts that the company will earn ($1.95) per share for the year, down from their prior estimate of ($1.57). The consensus estimate for Zevra Therapeutics' current full-year earnings is ($1.63) per share. Roth Capital also issued estimates for Zevra Therapeutics' Q4 2024 earnings at ($0.38) EPS, Q1 2025 earnings at ($0.30) EPS, Q2 2025 earnings at ($0.12) EPS, Q3 2025 earnings at ($0.04) EPS, FY2025 earnings at ($0.31) EPS, FY2026 earnings at $0.67 EPS, FY2027 earnings at $1.41 EPS and FY2028 earnings at $1.85 EPS.

Several other research analysts have also recently commented on the stock. Canaccord Genuity Group reduced their target price on shares of Zevra Therapeutics from $25.00 to $23.00 and set a "buy" rating for the company in a report on Thursday. Maxim Group increased their price objective on shares of Zevra Therapeutics from $18.00 to $25.00 and gave the stock a "buy" rating in a research note on Tuesday, September 24th. William Blair raised Zevra Therapeutics to a "strong-buy" rating in a research report on Friday, August 30th. JMP Securities assumed coverage on Zevra Therapeutics in a research report on Tuesday, September 24th. They set an "outperform" rating and a $17.00 price target for the company. Finally, Roth Mkm boosted their price target on Zevra Therapeutics from $19.00 to $21.00 and gave the stock a "buy" rating in a research report on Tuesday, September 24th. Seven analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the company currently has an average rating of "Buy" and a consensus target price of $21.00.

Zevra Therapeutics Stock Down 4.5 %

Shares of ZVRA traded down $0.41 during mid-day trading on Friday, hitting $8.62. 1,369,032 shares of the company's stock were exchanged, compared to its average volume of 548,353. The company has a debt-to-equity ratio of 1.80, a current ratio of 2.00 and a quick ratio of 2.00. Zevra Therapeutics has a 52 week low of $4.18 and a 52 week high of $9.21. The company has a market cap of $453.57 million, a PE ratio of -4.58 and a beta of 1.93. The company has a 50-day simple moving average of $7.97 and a 200 day simple moving average of $6.44.

Zevra Therapeutics (NASDAQ:ZVRA - Get Free Report) last announced its earnings results on Tuesday, August 13th. The company reported ($0.48) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.47) by ($0.01). Zevra Therapeutics had a negative net margin of 342.63% and a negative return on equity of 177.96%. The firm had revenue of $4.45 million during the quarter, compared to analyst estimates of $4.08 million. During the same period in the prior year, the business posted ($0.15) EPS.

Institutional Trading of Zevra Therapeutics

Hedge funds have recently made changes to their positions in the business. MetLife Investment Management LLC raised its stake in Zevra Therapeutics by 8.1% in the 3rd quarter. MetLife Investment Management LLC now owns 22,866 shares of the company's stock valued at $159,000 after acquiring an additional 1,717 shares during the period. City State Bank increased its holdings in shares of Zevra Therapeutics by 14.1% in the third quarter. City State Bank now owns 16,224 shares of the company's stock valued at $113,000 after purchasing an additional 2,000 shares during the last quarter. The Manufacturers Life Insurance Company raised its position in shares of Zevra Therapeutics by 15.2% in the second quarter. The Manufacturers Life Insurance Company now owns 18,573 shares of the company's stock valued at $91,000 after purchasing an additional 2,452 shares during the period. International Assets Investment Management LLC lifted its stake in shares of Zevra Therapeutics by 594.0% during the 3rd quarter. International Assets Investment Management LLC now owns 6,940 shares of the company's stock worth $48,000 after buying an additional 5,940 shares during the last quarter. Finally, IFG Advisors LLC boosted its holdings in shares of Zevra Therapeutics by 41.2% during the 3rd quarter. IFG Advisors LLC now owns 26,400 shares of the company's stock worth $183,000 after buying an additional 7,700 shares during the period. 35.03% of the stock is owned by institutional investors and hedge funds.

Zevra Therapeutics Company Profile

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy.